Trial Profile

A prospective, open-label, single-arm, multicenter study to evaluate the visualization ability and safety of 68Ga-PSMA-11 PET/CT compared with conventional imaging (CT and bone scintigraphy) in Japanese patients with biochemically recurrent prostate cancer who had undergone curative treatment

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Feb 2026 According to Telix Pharmaceuticals media release, the first patient has been dosed in the trial at Shonan Kamakura General Hospital (SKGH) in Kamakura, Japan. And , the data from the trial is intended to support a future marketing authorization application for TLX591-Px in Japan.
12 Feb 2026 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com